25‐Hydroxyvitamin D Levels and Markers of Subclinical Myocardial Damage and Wall Stress: The Atherosclerosis Risk in Communities Study

Michos, Erin D.; Selvin, Elizabeth; Misialek, Jeffrey R.; McEvoy, John W.; Ndumele, Chiadi E; Folsom, Aaron R.; Ballantyne, Christie M.; Lutsey, Pamela L.

doi:10.1161/jaha.116.003575

Cited by 11 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An inverse correlation between the vitamin D level and the stage of coronary atherosclerosis along with the levels of total cholesterol, LDL and triglycerides in women and men over 70 years has been reported [100]. Similarly, low levels of vitamin D have been associated with subclinical atherosclerosis, increased expression of high-sensitivity cardiac troponin T and N-terminal pro–brain natriuretic peptide (markers of subclinical myocardial damage and wall stress) [101]. In addition, the role of vitamin D binding protein (VDBP) and its polymorphism in relation to atherosclerosis and the role of VDBP in resistance to atherosclerosis leading to the longevity of patients have also been examined [102].…”

Section: Vascular Diseasementioning

confidence: 99%

Role of Vitamin D in Cardiovascular Diseases

Rai

Agrawal

2017

Endocrinology and Metabolism Clinics of North America

118

View full text Add to dashboard Cite

Vitamin D is critical in mineral homeostasis and skeletal health, and plays regulatory role in non-skeletal tissues. Vitamin D deficiency is associated with chronic inflammatory diseases, including diabetes and obesity both being strong risk factors for cardiovascular diseases (CVD). CVD, including coronary artery disease, myocardial infarction, hypertrophy, cardiomyopathy, cardiac fibrosis, heart failure, aneurysm, peripheral arterial disease, hypertension, and atherosclerosis, are major causes of morbidity and mortality worldwide. The association of these diseases with vitamin D deficiency and improvement with vitamin D supplementation suggest its therapeutic benefit. Here, we critically review the recent findings on the association of vitamin D deficiency and CVD.

show abstract

Section: Vascular Diseasementioning

confidence: 99%

Role of Vitamin D in Cardiovascular Diseases

Rai

Agrawal

2017

Endocrinology and Metabolism Clinics of North America

118

View full text Add to dashboard Cite

show abstract

“…The inverse correlation between cTnT and VIT-D 3 blood levels was reported in many clinical studies, where low VIT-D 3 levels were associated with raised CTnT levels (Hur et al, 2009;Michos et al, 2016). Likewise, a recent study showed that supplementation of VIT-D 3 significantly reduced cTnT in breast cancer treatment with adjuvant DX chemotherapy (El-Bassiouny et al, 2022).…”

Section: Scintigraphic Assaymentioning

confidence: 84%

Electrocardiographic, biochemical, and scintigraphic evidence for the cardioprotective effect of paricalcitol and vitamin D3 on doxorubicin-induced acute cardiotoxicity in rats

KOROGLU,

AYGUN

2024

BLL

View full text Add to dashboard Cite

AIM: We aimed to investigate the possible cardioprotective effects of paricalcitol (PR), its vitamin D receptor agonist, and vitamin D 3 (VIT-D3) on an experimental model of doxorubicin (DX) cardiotoxicity by 99m Tc-PYP scintigraphy, electrocardiographic (ECG) and biochemical methods. METHOD: Forty-two male Wistar/Albino rats (250-300 g; aged 10-12 weeks) were randomly separated into six groups, namely into control (CN), doxorubicin (DX), paricalcitol (PR), vitamin D 3 (VIT-D 3 ), paricalcitol + doxorubicin (PR+DX), and vitamin D 3 + doxorubicin (VIT-D 3 +DX) groups. Cardiotoxicity was induced by three doses of DX (18 mg/kg, i.p.) at 24-hour intervals on days 18, 19 and 20. PR (0.5 ug/ kg, i.p) and VIT-D 3 (5,000 IU/kg, i.p) were injected for 20 days before and after the application of DX (18 mg/kg, i.p.). On day 21 of the experiment, biochemical parameters [tumor necrosis factor TNF-alpha (TNF-α); interleukin-6 (IL-6), nitric oxide (NO), and cardiac troponin T (cTnT)], as well as ECG and scintigraphic ( 99m Tc-PYP) features were assessed. RESULTS: Compared to CN, DX significantly raised TNF-α, IL-6, and NO in heart tissue, cTnT in serum, 99m Tc-PYP uptake in the myocardium, and ECG parameters, specifically QRS complex duration, QT interval duration, and ST-segment amplitude, while also reducing heart rate (p<0.001). Pretreatment with PR and VIT-D 3 mitigated these abnormalities produced by DX in the heart (p<0.001). CONCLUSION: Results show that vitamin D receptor agonist paricalcitol and vitamin D protect against DX-induced cardiotoxicity through anti-inflammatory and antioxidant effects (Fig. 4, Ref. 59).

show abstract

“…Methods for ascertaining participant characteristics and laboratory measures in ARIC have previously been described 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 and are detailed in Data S1 . All laboratory measures were performed at visit 5.…”

Section: Methodsmentioning

confidence: 99%

Association of Pulmonary Function With Late‐Life Cardiac Function and Heart Failure Risk: The ARIC Study

Ramalho

Claggett

Washko

et al. 2022

JAHA

View full text Add to dashboard Cite

Background Pulmonary and cardiac functions decline with age, but the associations of pulmonary dysfunction with cardiac function and heart failure (HF) risk in late life is not known. We aimed to determine the associations of percent predicted forced vital capacity (ppFVC) and the ratio of forced expired volume in 1 second (FEV 1 ) to forced vital capacity (FVC; FEV 1 /FVC) with cardiac function and incident HF with preserved or reduced ejection fraction in late life. Methods and Results Among 3854 HF‐free participants in the ARIC (Atherosclerosis Risk in Communities) cohort study who underwent echocardiography and spirometry at the fifth study visit (2011–2013), associations of FEV 1 /FVC and ppFVC with echocardiographic measures, cardiac biomarkers, and risk of HF, HF with preserved ejection fraction, and HF with reduced ejection fraction were assessed. Multivariable linear and Cox regression models adjusted for demographics, body mass index, coronary disease, atrial fibrillation, hypertension, and diabetes. Mean age was 75±5 years, 40% were men, 19% were Black, and 61% were ever smokers. Mean FEV 1 /FVC was 72±8%, and ppFVC was 98±17%. In adjusted analyses, lower FEV 1 /FVC and ppFVC were associated with higher NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide; both P <0.001) and pulmonary artery pressure ( P <0.004). Lower ppFVC was also associated with higher left ventricular mass, left ventricular filling pressure, and high‐sensitivity C‐reactive protein (all P <0.01). Lower FEV 1 /FVC was associated with a trend toward higher risk of incident HF with preserved ejection fraction (hazard ratio [HR] per 10‐point decrease, 1.31; 95% CI, 0.98–1.74; P =0.07) and HF with reduced ejection fraction (HR per 10‐point decrease, 1.24; 95% CI, 0.91–1.70; P =0.18), but these associations did not reach statistical significance. Lower ppFVC was associated with incident HF with preserved ejection fraction (HR per 10‐unit decrease, 1.21; 95% CI, 1.04–1.41; P =0.013) but not with HF with reduced ejection fraction (HR per 10‐unit decrease, 0.90; 95% CI, 0.76–1.07; P =0.24). Conclusions Subclinical reductions in FEV 1 /FVC and ppFVC differentially associate with cardiac function and HF risk in late life.

show abstract

25‐Hydroxyvitamin D Levels and Markers of Subclinical Myocardial Damage and Wall Stress: The Atherosclerosis Risk in Communities Study

Cited by 11 publications

References 43 publications

Role of Vitamin D in Cardiovascular Diseases

Role of Vitamin D in Cardiovascular Diseases

Electrocardiographic, biochemical, and scintigraphic evidence for the cardioprotective effect of paricalcitol and vitamin D3 on doxorubicin-induced acute cardiotoxicity in rats

Association of Pulmonary Function With Late‐Life Cardiac Function and Heart Failure Risk: The ARIC Study

Contact Info

Product

Resources

About